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Myotonic dystrophy (DM) of type 1 and 2 (DM1 and DM2) are inherited autosomal
dominant diseases caused by dynamic and unstable expanded microsatellite sequences
(CTG and CCTG, respectively) in the non-coding regions of the genes DMPK and
ZNF9, respectively. These mutations result in the intranuclear accumulation of mutated
transcripts and the mis-splicing of numerous transcripts. This so-called RNA gain
of toxic function is the main feature of an emerging group of pathologies known
as RNAopathies. Interestingly, in addition to these RNA inclusions, called foci, the
presence of neurofibrillary tangles (NFT) in patient brains also distinguishes DM as a
tauopathy. Tauopathies are a group of nearly 30 neurodegenerative diseases that are
characterized by intraneuronal protein aggregates of the microtubule-associated protein
Tau (MAPT) in patient brains. Furthermore, a number of neurodegenerative diseases
involve the dysregulation of splicing regulating factors and have been characterized
as spliceopathies. Thus, myotonic dystrophies are pathologies resulting from the
interplay among RNAopathy, spliceopathy, and tauopathy. This review will describe
how these processes contribute to neurodegeneration. We will first focus on the
tauopathy associated with DM1, including clinical symptoms, brain histology, and
molecular mechanisms. We will also discuss the features of DM1 that are shared
by other tauopathies and, consequently, might participate in the development of a
tauopathy. Moreover, we will discuss the determinants common to both RNAopathies
and spliceopathies that could interfere with tau-related neurodegeneration.
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INTRODUCTION
Myotonic dystrophy (DM) of type I (DM1), which is also referred
to as dystrophia myotonica or Steinert’s disease, is the most
common form of adult-onset muscular dystrophy and affects at
Abbreviations: 3′ UTR, 3′ untranslated region; Aβ, amyloid beta; AD, Alzheimer’s
disease; ALS, amyotrophic lateral sclerosis; APP, amyloid-β precursor protein;
BBB, blood-brain barrier; Bin-1, bridging integrator-1; CBD, corticobasal degen-
eration; CELF, CUG-BP and ETR-3-like factor; CELF1, CUG-binding protein
1 (CUG-BP1); CELF2, CUGBP2 or ETR-3; CNS, central nervous system; CSF,
cerebrospinal fluid; DLB, dementia with Lewy bodies; DM, myotonic dystro-
phy; DM1, myotonic dystrophy of type 1; DM2, myotonic dystrophy of type 2;
DMPK, myotonic dystrophy protein kinase; DS, Down syndrome; EDS, exces-
sive daytime sleepiness; FAT, fast anterograde transport; FISH, fluorescence in situ
hybridization; FTD, frontotemporal dementia; FTDP-17, frontotemporal demen-
tia and parkinsonism linked to chromosome 17; FUS, fused in sarcoma; GVD,
granulovacuolar degeneration; hnRNP, heterogeneous nuclear ribonucleoprotein;
IR, insulin resistance; IRES, internal ribosome entry site; KO, Knockout; LB,
Lewy bodies; MAPT, microtubule-associated protein tau; MB, Marinesco bod-
ies; MBNL, Muscleblind-like; MBR, microtubule-binding repeats; MRI, magnetic
resonance imaging; NFD, neurofibrillary degeneration; NFT, neurofibrillary tan-
gle; NMDAR, N-methyl-D-aspartate receptors; ORF, open reading frame; PAD,
phosphatase activating domain; PD, Parkinson’s disease; PiD, Pick’s disease; PRD,
proline-rich domain; PROMM, proximal myotonic myopathy; PS, presenilin; PSP,
progressive supranuclear palsy; RAN, Repeat-associated non-ATG-initited transla-
tion; RBP, RNA-binding proteins; SMA, spinal muscular atrophy; SMN, survival
of motor neurons; SNPs, single nucleotide polymorphisms; snRNP, small nuclear
ribonucleoprotein; T2DM, type II diabetes; TDP-43, TARDNA-binding protein 43.
least 1 in 8000 people worldwide. DM1 is an inherited autosomal
dominant disease caused by the dynamic and unstable expan-
sion of a trinucleotide CTG repeat motif in the 3′ UTR of the
DMPK gene located at q13.3 on chromosome 19 (Brook et al.,
1992). Affected individuals carry CTG copy numbers greater
than 50 and present a highly variable phenotype, ranging from
asymptomatic to a severe congenital form of the disease. The
length of CTG expansion has been associated with the severity
of the pathology and is dependent on both meiotic and somatic
instability (Mahadevan et al., 1992; Harley et al., 1993; Wong
et al., 1995; Martorell et al., 1998). This inherited neuromuscu-
lar disease affects multiple organs, including skeletal and smooth
muscles (distal muscular atrophy, myotonia, muscle weakness
grip and wasting, percussion myotonia hatchet face, and ptosis),
the heart (arrhythmia and conduction defects), the endocrine sys-
tem (hyperinsulinemia), eyes (cataracts), gonads (atrophy), the
central nervous system (CNS) (executive and visuoconstructive
difficulties, facial emotion recognition impairment, and neu-
ropsychiatric symptoms), and the peripheral nervous system
(axonal peripheral neuropathy) (cf reviews: Schara and Schoser,
2006; Turner and Hilton-Jones, 2010; Romeo, 2012).
The mechanisms underlying DM1 physiopathology have
recently begun to be elucidated. DM1 is the first identified disease
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resulting from a repeat expansion in a non-coding region of
mRNA. Thus, the toxic effect of the CTG expansion seems to be
more associated with the expression of mutated DMPK RNA than
with changes in the expression of the DMPK protein. Substantial
evidence supports a pathogenic role for these non-coding repeats
at the RNA level, such as the discovery of a second type of
DM, DM2 (or PROMM, proximal myotonic myopathy), which
is due to a CCTG repeat expansion in another non-coding part
of another transcript, the first intron of the ZNF9 gene (Liquori
et al., 2001). The nuclear export of the mutated RNAs is defective,
and they subsequently accumulate and aggregate to form so-
called nuclear foci, which then recruit and sequester RNA-binding
proteins (RBP) [reviewed in Day and Ranum (2005), Schoser
and Timchenko (2010)]. The identification of new pathologies
presenting a similar RNA toxicity associated with repeat expan-
sions, foci appearance, and the sequestration of RBP led to the
identification of these disorders as RNAopathies (Renoux and
Todd, 2012). The subsequent loss of function of these RBP
leads to a disruption in RNA metabolism, including modifi-
cations of the alternative splicing of numerous pre-messenger
RNAs in several tissues. This altered process highly contributes
to the multisystemic effect of the DM1 mutation [reviewed in
Kuyumcu-Martinez and Cooper (2006); Ranum and Cooper
(2006)]. Other mechanismsmight interfere with pathology devel-
opment. The haploinsufficiency of the protein encoded by the
mutated allele and the cis-effect of the mutation on neighbor-
ing genes have been explored (Fu et al., 1993; Novelli et al., 1993;
Otten and Tapscott, 1995; Thornton et al., 1997). More recently,
themutation inDM1 has been suggested to have additional effects
on the translation and stability of proteins, generation of toxic
anti-sense transcripts, and expression of toxic homopolymeric
peptide species through a non-ATG initiated translation pathway
[recently reviewed in Klein et al. (2011), Sicot et al. (2011)].
Interest in the neurological aspects of DM has increased in
the last several years. Reviews and workshops of these studies
have primarily focused on clinical symptoms and neuroimaging
(Axford and Pearson, 2013). This review highlights a particular
aspect of DM neurological disorders, the tauopathy. Tauopathies
are neurodegenerative diseases characterized by the intraneuronal
aggregation of microtubule-binding Tau proteins. The aim of this
review is to describe the different aspects of the Tau pathology
observed in DM1, including clinical symptoms, brain histology,
and molecular mechanisms. We will also discuss the features of
DM1 that are shared by other tauopathies and neurodegenera-
tive diseases and that might contribute to the development of
tauopathies. Moreover, we will focus on the possible interac-
tions between the mechanisms of RNAopathy, spliceopathy, and
tauopathy in the development of DM brain pathology.
DM NEUROPATHOLOGICAL SIGNS AND TAUOPATHY
FEATURES
CLINICAL SYMPTOMS
Cognitive impairment in DM1 has been clearly established. DM1
patients exhibit changes in personality traits and/or mood dis-
orders (Rubinsztein et al., 1998; Meola et al., 2003; Antonini
et al., 2006; Winblad et al., 2006b). The cerebral involve-
ment of DM1 patients has been associated with difficulties
in executive functions (D’Angelo and Bresolin, 2003), visu-
ospatial/constructive abilities (Malloy et al., 1990), memory
(Rubinsztein et al., 1997), facial emotion recognition (Winblad
et al., 2006a), and psychomotor delay. Apathy (Rubinsztein et al.,
1998), avoidance (Meola et al., 2003), depression and anxiety
(Antonini et al., 2006), anhedonia, and decreased emotional par-
ticipation are often the main neurological and clinical symptoms
of this pathology (Bungener et al., 1998). Approximately one third
of DM1 patients also suffer from excessive daytime sleepiness
(EDS) that most likely results from CNS disturbance [reviewed in
Laberge et al. (2013)]. Consistent with this observation, MBNL2
KO transgenic mice, which are characterized by neurodegener-
ative symptoms in the absence of obvious muscle alterations,
develop hypersomnia (Charizanis et al., 2012). In the most severe
cases of DM1 (congenital/juvenile form), mental retardation has
also been described [reviewed in Machuca-Tzili et al. (2005);
Schara and Schoser (2006)]. Furthermore, approximately half of
these young patients also have autism spectrum disorders, the fre-
quency of which is related to the number of CTG repeat (Ekstrom
et al., 2008).
Brain involvement in DM2 is more controversial. Similar cog-
nitive and behavioral dysfunctions are described, with milder
manifestations compared with DM1 (Meola et al., 2003; Weber
et al., 2010). In contrast to DM1, DM2 has not been associated
with developmental abnormalities and thus does not cause severe
childhood symptoms. This difference likely explains why nomen-
tal retardation similar to that reported in congenital and juvenile
forms of DM1 has been described in DM2 patients.
NEUROIMAGING
MRI studies have revealed global cerebral atrophy with dilated
ventricles in DM1 (Censori et al., 1994; Antonini et al., 2004).
No correlation has been observed between brain tissue volumes
and the grade of pathology, disease duration, or CTG expan-
sion. However, the potential correlation between brain tissue
volume and CTG expansion remains unclear because these stud-
ies were performed using repeat lengths measured from blood
cells and not from brain tissue, where the somatic instability of
CTG expansion is particularly obvious and varies both with a
single brain area and between different areas. Indeed, the expan-
sion length can vary from 150 to more than 3000 CTG repeats
(Sergeant et al., 2001; Dhaenens et al., 2011). Furthermore, a
large difference in the CTG expansion length between muscle and
blood has recently been reported, confirming that the CTG length
depends on the tissue analyzed (Nakamori et al., 2013). Thus,
the potential correlation between brain imaging alterations and
CTG repeat length in the altered regions remains unclear. Future
follow-up clinical studies are needed to support a correlation.
In DM1, cortical gray matter loss is primarily observed in the
frontal, parietal, and occipital regions and in the superior and
middle temporal gyrus, whereas subcortical gray matter loss is
detected in thalamic and basal ganglia structures (Antonini et al.,
2004; Weber et al., 2010; Minnerop et al., 2011). These areas are
involved in cognitive dysfunctions and personality disorders, such
as apathy, depression, anxiety, and deficits in attention, mem-
ory, and visuospatial function (Antonini et al., 2004). Cortical
atrophy has also been observed in DM2, although to a lesser
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extent than in DM1 (Ota et al., 2006; Minnerop et al., 2008,
2011).
White matter lesions are more pronounced than gray mat-
ter lesions in the DM1 brain. Regression analyses have revealed
associations between affected white matter and several clinical
parameters in both DM1 and DM2, but no associations with
neuropsychological performance have been described (Minnerop
et al., 2011). A recent study of children and adolescents suggested
a relationship between white matter damage and working mem-
ory (Wozniak et al., 2013). White matter lesions are detected
throughout the whole brain in DM types 1 and 2, affecting
association fibers, commissural fibers (primarily in the corpus
callosum), and projection fibers in the brainstem and the internal
and external capsules, which connect the prefrontal and tempo-
ral cortical areas with the striatum. Although white matter lesions
are also present in the frontal regions of patient brains, lesions
located within anterior temporal lobes are considered a charac-
teristic feature in DM patients (Hund et al., 1997; Di Costanzo,
2001; Naka et al., 2002; Kassubek et al., 2003; Kornblum et al.,
2004; Fukuda et al., 2005; Vielhaber et al., 2006; Minnerop et al.,
2011). These lesions demonstrate familial aggregation in DM1
and could be progressive along the disease evolution in associa-
tion with CTG length (Di Costanzo, 2001; Ota et al., 2006; Romeo
et al., 2010; Minnerop et al., 2011). Moreover, “état criblé” in the
cerebral deep white matter has recently been reported (Itoh et al.,
2010). Furthermore, hypoperfusion and glucose hypometabolism
in the frontal and temporal lobes have been observed in DM,
although these features are present to a greater extent in the DM1
brain than in the DM2 brain (Meola et al., 1999; Weber et al.,
2010).
HISTOLOGY
Foci
Mutated DMPK transcripts with abnormally expanded CUG
repeats are retained and accumulated in RNA nuclear inclusions
called foci, which were first observed in DM1 muscle biop-
sies (Taneja et al., 1995). These foci have also been observed
in human DM1 brains, particularly in the neuronal cells of the
cerebral cortex, hippocampus, dentate gyrus, thalamus, substan-
tia nigra, and brain stem tegmentum. A weak detection of foci
has also been reported in the oligodendrocytes of the subcorti-
cal white matter and corpus callosum (Jiang et al., 2004). These
nuclear RNA inclusions sequester RNA-binding proteins, such
as the splicing factors Muscleblind-like 1 (MBNL1) and MBNL2
(Miller et al., 2000; Fardaei et al., 2001, 2002; Jiang et al., 2004)
and to a lesser extent, heterogeneous nuclear ribonucleopro-
teins (hnRNPs) H and F (Jiang et al., 2004; Kim et al., 2005;
Paul et al., 2011). While hnRNP H has been suggested to pre-
vent the nuclear export of the mutated transcripts, MBNL1 has
been directly implicated in the formation and stabilization of
foci [(Kim et al., 2005; Querido et al., 2011); detailed below].
Interestingly, focus formation has also been observed in the brains
of transgenic DMSXL mice bearing more than 1000 CTG repeats
(Huguet et al., 2012) and in neuronal progeny derived from
human embryonic stem cells carrying the DM1 mutation, par-
ticularly neuronal cells with a motor neuron phenotype (Marteyn
et al., 2011).
Neurofibrillary degeneration (NFD)
NFD is an age-related process that occurs during normal
aging and is abnormally enhanced in neurodegenerative dis-
eases referred to as “tauopathies”. NFD is characterized by the
accumulation of intraneuronal argyrophilic fibers. This insolu-
ble material corresponds to the accumulation and aggregation
of hyperphosphorylated microtubule–associated Tau proteins,
which form neurofibrillary tangles (NFTs) [reviewed in Buee et al.
(2010)], mainly in neuron soma but also in neuropile threads,
similarly to that observed in an AD brain, whereas Tau proteins of
a healthy neuron are mainly located in the axon. First identified
in the brains of Alzheimer’s disease (AD) patients, NFD is now
considered a common neuronal feature in nearly 30 tauopathies
[reviewed in Sergeant et al. (2008)]. The spatiotemporal pro-
gression of the neurofibrillary lesions through the brains of AD
patients can be subdivided in 6 or 10 stages according to the
anatomopathological description of Braak and Braak (1991) or
the biochemical analysis of more than 20 brain regions from 200
individuals, respectively (Delacourte et al., 1999). The density and
topographic progression of NFTs have been correlated with dis-
ease severity and cognitive decline in AD patients (Duyckaerts
et al., 1997; Berg et al., 1998; Giannakopoulos et al., 2003; Bennett
et al., 2004). This observation strongly suggests a central role for
fibrillar Tau inclusions in the pathophysiology and clinical symp-
toms of AD. Furthermore, the propagation of Tau pathology has
recently been reported in animals after the injection of insoluble
material obtained from animal models of AD, the brains of AD
patients, or a lentivirus encoding wild type Tau (Clavaguera et al.,
2009, 2013; De Calignon et al., 2012; Lasagna-Reeves et al., 2012;
Caillierez et al., 2013).
This relationship between Tau inclusion and pathophysiol-
ogy is supported by the identification of autosomal dominant
mutations in the MAPT gene in various other tauopathies,
such as fronto-temporal dementia (FTD); these mutations are
sufficient to induce both clinical symptoms and Tau pathol-
ogy [reviewed in Schraen-Maschke et al. (2008), Umeda et al.
(2013)].
Is the cognitive dysfunction reported in DM1 associated
with the development of a tauopathy? Indeed, NFTs have been
observed in both DM1 and DM2 brains in the amygdala, CA1,
hippocampus, entorhinal cortex, and temporal cortex, then with
a topographic distribution similar to that reported for mod-
erate Alzheimer disease although the topographic progression
of Tau pathology during DM1 has not yet been clearly estab-
lished (Figure 1) (Yoshimura et al., 1990; Vermersch et al., 1996;
Delacourte et al., 1999; Maurage et al., 2005). Thus, DM can be
considered as a tauopathy-associated disease solely based on the
presence of NFTs (Yoshimura et al., 1990; Vermersch et al., 1996;
Sergeant et al., 2001; Maurage et al., 2005; Oyamada et al., 2006;
Itoh et al., 2010). Although a lower distribution of Tau inclusions
throughout the brain is observed in DM patients compared with
other pathologies, such as AD, the topographic distribution and
expression of NFTs are still higher than that in unaffected individ-
uals of the same age (Vermersch et al., 1996). Tau pathology pro-
gression in the DM brain is therefore considered moderate and is
close to Braak and Braak stage 3–4 based on the number of NFTs
observed.
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FIGURE 1 | Immunohistochemical analysis of the DM1 hippocampus
(CA1 region). (A) Detection of NFTs using three antibodies directed
against Tau phosphorylated Ser202-205 (AT8), phosphorylated Ser 262
(12E8), and phosphorylated Ser396-404 (AD2) (x200). (B) Absence of
amyloid detection using the Wo-2 antibody in samples obtained from
individuals with DM1 (x100). Positive control: AD brain (Alz) (×100).
Although all tauopathies are characterized by intraneuronal
Tau aggregates, their clinical symptoms and histopathological
criteria differ, including the structure of the aggregates (paired
helical filaments, straight filaments or Pick bodies), the cerebral
localization of degenerating neurons, the presence or absence of
glial Tau inclusions (astrocytic plaques, tuft-shaped astrocytes,
and oligodendroglial coiled bodies), and the association with
other types of neuropathological lesions, such as extracellular
amyloid deposits or Lewy bodies (LBs) [reviewed in Sergeant
et al. (2005)]. In DM1 brains, no amyloid/senile plaques have
been described (Figure 1), and α-synuclein inclusions (LBs) have
scarcely been observed (Kiuchi et al., 1991; James et al., 2012)
(Maurage and Sergeant, unpublished results). DM is therefore
different from AD or dementia with Lewy bodies (DLB) (Kiuchi
et al., 1991). However, as in many age-related neurodegenera-
tive disorders, a strong gliosis has been observed (Yoshimura
et al., 1990; Ono et al., 1995). Although neurodegenerating neu-
rons typically contain NFTs, the ultrastructure of these DM Tau
aggregates remains unknown.
The aggregate composition in Tau isoforms permits the
classification of the different tauopathies into five sub-groups
(reviewed in Sergeant et al., 2005). In the human adult brain, six
Tau protein isoforms are expressed through alternative splicing
of exons 2, 3, and 10 (Figures 2, 3). These isoforms are named
according to their splicing patterns: 2N3R, 1N3R, 0N3R, 2N4R,
1N4R, and 0N4R. Two other minor exons, 4A and 6, have also
been detected in mature brain RNA, but the levels of these tran-
scripts are low, and the corresponding proteins are not detected
in the brain. Depending on the disease, the Tau protein isoform
composition varies. All six Tau isoforms are aggregated in some
diseases, such as AD, whereas the preferential aggregation of 3R or
4R isoforms occurs in other diseases, such as Pick’s disease (PiD)
and progressive supranuclear palsy (PSP), respectively [reviewed
FIGURE 2 | Different splicing patterns of Tau- alternative exons leading
to the main expression of six isoforms in the adult brain: 2N3R, 1N3R,
0N3R, 2N4R, 1N4R, and 0N4R. The isoforms 0N, 1N, and 2N correspond
to the exclusion or inclusion of only exon 2 or both exons 2 and 3. Note that
exon 3 insertion is dependent on exon 2 insertion. The isoforms 3R and 4R
correspond to the exclusion or inclusion of exon 10, respectively. Note that
this figure only indicates the alternative splicing of coding exons. The
coding regions are colored in gray for constitutive exons and in yellow,
orange, pale purple, green, and blue for alternative exons 2, 3, 4A, 6, and
10, respectively. The inclusion of exons 4A and 6 occurs rarely in the brain
and is more prominently detected in the peripheral nervous system, and
the insertion of these exons varies according to the 3′ splicing site used.
These two exons are shaded because the corresponding protein isoforms
are not detected in the brain.
in Sergeant et al. (2005)]. DM is the only disease characterized by
the preferential aggregation of a single isoform: the smaller 0N3R
isoform (Vermersch et al., 1996). The primary expression of the
smaller protein could suggest mis-splicing of the Tau transcripts
in DM.
Interestingly, NFTs have also recently been reported in sym-
pathetic ganglions, suggesting a potential association with the
peripheral neuropathy observed in some DM1 patients (Kuru
et al., 2013; Peric et al., 2013b).
Other histological features
LBs, which are primarily composed of α-synuclein, are charac-
teristic of DLB and Parkinson’s disease (PD) but have also been
observed in mixed AD/LB dementia (Rosenblum and Ghatak,
1979; Gibb et al., 1989; Bose et al., 2008; Echavarri et al., 2012).
Interestingly, LBs have also been reported in DM brains in some
patients (Itoh et al., 2010), suggesting a possible mixed pathology
in these cases.
Analysis employing an anti-ubiquitin antibody revealed
Marinesco bodies (MB) in the substantia nigra, which are rarely
observed in DM1 patients but numerous in DM2 patients
(Maurage et al., 2005). AlthoughMBs have been detected in aging
persons, the frequency of these inclusions increases in several
diseases, such as DM.
Recently, a new histological feature has been reported in the
hippocampal neurons of DM patients (Yamazaki et al., 2011;
Nakamori et al., 2012). Granulovacuolar degeneration (GVD)
is characterized by the presence of double membrane-bound
cytoplasmic vacuoles, which are strongly detected using antibod-
ies directed against late-stage autophagic marker Lamp1. These
vacuoles contain an electron-dense granule that contains, at a
minimum, endosomal sorting complex required for transport
(ESCRT)-III subunits, charged multivesicular body protein 2B
(CHMP2B), ubiquitin, pSmad2/3, and phospho-TDP-43 (Braak
and Braak, 1991; Okamoto et al., 1991; Baig et al., 2009; Yamazaki
et al., 2010; Funk et al., 2011). Although detected in the hip-
pocampus in elderly persons, GVD is more frequently present
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FIGURE 3 | Schematic of the Tau isoforms. (A,B) isoforms primarily
expressed in fetal and adult brains, respectively, (C) poorly expressed in
brain. The different structural domains are indicated at the bottom of each
panel. The inserts in (B) represent the differential expression of Tau isoforms
in the adult brain, and the tissue specificity of the splicing is illustrated by
comparison with skeletal muscle expression; the width of the diagram
corresponds to level of the corresponding isoform [drawn from Mulot et al.
(1994), Boutajangout et al. (2004), Andreadis (2005), Trabzuni et al. (2012)].
Exon 4A Short and Long and exons 6c, p, and d correspond to distinct 3′ sites
in exons 4A and 6 (panel C) (Wei and Andreadis, 1998; Souter and Lee, 2010).
The inclusion of 6p and 6d results in a change in the open reading frame
(ORF) and introduces a stop codon, leading to the expression of truncated
proteins. Note that the inclusion of exons 3, 6, and 4A occurs rarely in the
brain. As shown in the insert in (C), exon 6 is primarily detected in muscle
compared with the brain (Andreadis, 2005). Exon 4A is primarily expressed in
the peripheral nervous system (Couchie et al., 1992; Georgieff et al., 1993),
and few data are available concerning this exon. PRD, proline-rich domain;
MBR, microtubule-binding repeat: R1–R4.
in AD patients. The GVD load increases with disease severity,
NFD, and the decline of episodic memory in AD (Ball, 1977;
Ball and Lo, 1977; Ghoshal et al., 2002). GVD has also been
reported in other neurodegenerative diseases, such as PiD, PSP,
and cortico-basal degeneration (CBD) (Yamazaki et al., 2011).
DM1 AND TAU MIS-SPLICING
EVIDENCE FOR TAU MIS-SPLICING
Tau mis-splicing was first suggested by an abnormal pattern of
pathological Tau proteins in the brain tissue of DM1 patients
compared with the prototypical quadruplet of pathological tau
proteins in the brains of AD patients (Vermersch et al., 1996). Tau
mis-splicing in DM1 has clearly been demonstrated at the RNA
and protein levels. Thus, in the DM1 brain, there is an overall
reduction of Tau protein isoforms with the sequence encoded by
exons 2 and 3 due to a deficit in the alternative splicing of these
exons (Sergeant et al., 2001; Leroy et al., 2006a). Thus, an exon
2-specific antiserum reveals NFT staining in AD brains but not
DM1 brains (Maurage et al., 2005). In addition to exons 2 and
3, the mis-splicing of Tau has also been reported for exon 10,
although this inclusion defect occurs to a lesser extent compared
with exon 2 and is not observed in all DM1 brains (Jiang et al.,
2004; Dhaenens et al., 2011). We also reported the defective splic-
ing of the minor Tau exon 6 brain cassette (Wei and Andreadis,
1998; Leroy et al., 2006a). Exon 6 is included in the mature mRNA
through one of three potential 3′ splice sites, leading to the inser-
tion of the 6c, 6p, or 6d forms (Figure 2; Andreadis, 2005). A
decrease in exon 6c and an increase in 6d have been observed in
DM1 brains (Leroy et al., 2006a). Although primarily expressed
in the brain, Tau is also expressed in various tissues, and the alter-
native splicing of this protein is tissue specific. Interestingly, the
alteration of Tau alternative splicing in DM1 also seems to be tis-
sue specific, as mis-splicing of exon 2 is observed in both brain
and skeletal muscle, whereas mis-splicing of exon 6 (decrease in
exon 6c and increase in 6d) is only observed in the brain (Leroy
et al., 2006a).
MECHANISMS
Two protein families, CELF and MBNL, have been implicated in
the mis-regulation of the alternative splicing of muscle and heart
transcripts in DM1, including cTNNT2, IR, and ClC-1 (Philips
et al., 1998; Ladd et al., 2001; Savkur et al., 2001; Charlet-B
et al., 2002; Kanadia et al., 2003; Ho et al., 2004; Kino et al.,
2009). In these tissues, CELF1 and MBNL1 are antagonistic reg-
ulators of many splicing events altered in DM1, and these events
are oppositely regulated during development: CELF1 expression
decreases whereas MBNL1 increases during heart development in
mice (Kalsotra et al., 2008). Thus, the sequestration of MBNL1 by
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mutated RNAs and the steady-state level of CELF1 in DM1 tissues
reproduces the fetal level of these factors, leading to a fetal-type
pattern of splicing [recently reviewed in Lee and Cooper (2009),
Mastroyiannopoulos et al. (2010), Klein et al. (2011)].
Studies aiming to understand the pathogenic mechanisms
involved in mis-splicing events in the brain are less numerous
than those concerning mis-splicing in skeletal muscle and the
heart. Only Tau is currently being studied. The eventual role of
CELF and MBNL proteins in Tau mis-splicing has been inves-
tigated for exons 2, 6, and 10, as described below. No data are
available concerning the dysregulation of Tau exon 3 splicing.
This cassette is rarely included in adult brain Tau transcripts, and
few data are available concerning the normal splicing regulation
of this exon. However, studies have shown that the inclusion of
exon 3 is dependent on the insertion of exon 2 and a weak branch
point/poly Y region (Wei and Andreadis, 1998; Arikan et al., 2002;
Andreadis, 2005; Trabzuni et al., 2012).
CELF family involvement
CELF1 (CUG-BP1) was the first CELF protein to be associated
with mis-splicing events in the muscle and heart of DM1 patients
[reviewed in Cho and Tapscott (2007)]. CELF1 is inefficient in the
splicing of Tau exons 2, 6, and 10 (Leroy et al., 2006b; Dhaenens
et al., 2011). However, CELF2 (ETR-3) acts as a silencer for
both exons 2 and 10 but is inefficient in silencing exon 6 (Leroy
et al., 2006a,b; Dhaenens et al., 2011). The role of CELF4 is
more ambiguous because this protein inhibits exon 2 inclusion,
favors the inclusion of exon 10, and, similar to CELF2, ineffi-
ciently modifies exon 6 splicing (Leroy et al., 2006a,b; Dhaenens
et al., 2011). CELF5 and CELF6 are the only two CELF mem-
bers that modify exon 6 splicing and reproduce its DM1 splicing
pattern when over-expressed via cell transfection (Leroy et al.,
2006a). Notably, neither of these proteins is expressed in muscle;
whereas CELF6 is expressed in a subset of tissues, such as brain,
kidney, and testis, CELF5 is principally expressed in the brain
(Ladd et al., 2001, 2004). This expression pattern could explain
why Tau exon 6 mis-splicing is brain specific and suggests that
CELF 5 and 6 might play a key role in this specific mis-splicing
(Leroy et al., 2006b). These results confirm the complexity and
independent regulation of Tau exon splicing in terms of expres-
sion profile and regulation, consistent with Andreadis’s results
(2005). The different levels of splicing alterations for each exon
in DM1 might reflect this complexity. Several members of the
CELF family could contribute to the global mis-splicing pattern
of Tau in the same tissue, but each protein might play a specific
role for a given Tau exon. Furthermore, the inefficient regulation
of Tau splicing by CELF1 suggests that the Tau exon 2mis-splicing
reported in muscle does not result from an increase in CELF1
activity, similar to other DM1-regulated transcripts, such as Bin-1
(Fugier et al., 2011). Rather, Tau exon 2 mis-splicing might result
from the activity of other CELF members, such as CELF2 (Leroy
et al., 2006b). An increase in CELF2 activity has been reported
in an inducible heart-specific DM1 mouse model (Wang et al.,
2007). Similar to the brain, CELF factors other than CELF1 and
CELF2 may participate in Tau splicing regulation in muscle; this
mechanism has been proposed for other deregulated transcripts
in DM. Indeed, Kino et al. reported that CELF 3, 4, 5, and 6
but not CELF1 and CELF2 regulate ClC-1 splicing (Kino et al.,
2009).
The different roles of the CELF factors for different Tau exons
could explain, at least in part, why the relative exclusion of the
main mis-spliced Tau exons in DM, exon 2 and exon 10, differs.
Indeed, the exclusion of exon 2 is more important than that of
exon 10, and an increase in exon 10 exclusion was not observed
in all DM1 brains, in contrast to exon 2 (Jiang et al., 2004;
Dhaenens et al., 2011). The CUG expansion length and Tau poly-
morphism do not play a role in exon 10mis-splicing susceptibility
(Dhaenens et al., 2011). By contrast, variations in exon 10 splicing
might be associated with CELF protein expression in the brain.
Indeed, CUG-BP1 and CELF2 protein expression varies greatly in
DM1 brains: both increased and decreased expression has been
observed compared with controls. By contrast, the expression of
CELF4 was stable and similar to that of the control (Dhaenens
et al., 2011). Interestingly, the brains with greater CELF1 and 2
levels also exhibit variations in exon 10 splicing. Although these
observations are correlative, these results suggest the stabilization
and activation of at least some of the CELF proteins in the brain,
perhaps through a phosphorylation mechanism as described for
CELF1 in muscles (Kuyumcu-Martinez et al., 2007, Dhaenes and
Sergeant unpublished result].
Moreover, the differing actions of CELF factors on different
Tau exons support our hypothesis that Tau exons are indepen-
dently regulated and further suggest that the splicing misregula-
tions observed during DM1 do not reflect a unique mechanism,
consistent with the hypothesis of Jiang et al. (2004) concerning
APP, Tau, and NMDAR mis-splicing.
MBNL family involvement
Interestingly, by favoring fetal-type splicing events, the DM1
mutation favors the expression of long fetal MBNL1 isoforms
in DM1 brains, as observed in DM1 muscles (Lin et al., 2006;
Dhaenens et al., 2008). Notably, this change is compatible with
an increase in MBNL1 nuclear localization and then poten-
tially in its depletion through sequestration in foci (Tran et al.,
2011). Mimicking the MBNL1 sequestration in foci, the silenc-
ing of MBNL1 expression in cellular models results in the loss
of Tau exon 2 insertion, similar to that observed in DM1 brain
splicing (Dhaenens et al., 2008, 2011). Surprisingly, Tau splicing
remains unchanged in the brains of MBNL1 KO mice, a model
that reproduces some of the muscle abnormalities, the cataracts,
and the mis-splicing of some RNA transcripts, such as TNNT2
and TNNT3, observed in DM1 (Kanadia et al., 2003; Suenaga
et al., 2012). In contrast to the MBNL1 KO model, the prefer-
ential exclusion of Tau exons 2 and 3 is observed in mice lacking
MBNL2, a new model that reproduces the brain but not muscle
pathology of DM1 (Charizanis et al., 2012). Exon 10 splicing has
not been reported in this MBNL2 KO model. Similar to exon 2,
MBNL1 silencing also favors exon 6 exclusion in a manner simi-
lar to that observed in the DM1 brain, whereas exon 10 splicing
is not modified (Leroy et al., 2006a; Dhaenens et al., 2011). This
last result is consistent with the differential regulation of exon
2 and 10 splicing, as reported in CELF regulation. However, the
results of a recent study concerning the impact of MBNL1 silenc-
ing efficiency on the number and severity of splicing alterations
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in a myoblast model suggest a need to re-examine the influence
of MBNL1 activity on Tau exon 10 regulation in a more robust
inducible system using stable cell lines (Jog et al., 2012).
EFFECTS OF DM1 MIS-SPLICING ON TAU FUNCTION
Splicing is a discrete cellular mechanism to modulate protein
function. Thus, mis-splicing leads to modifications of protein
activity. Most of the tauopathies for which an alteration of Tau
alternative splicing has been reported are characterized by an
alteration of exon 10 inclusion/exclusion. Thus, three isoforms
are expressed according to the insertion or exclusion of exons 2
and 3 (Sergeant et al., 2008). DM is the only tauopathy charac-
terized by the extensive alteration of Tau splicing involving exons
2, 3, 6, and 10, resulting in the primary expression of only one
isoform. Although the role of each exon-coded sequence is not
well-defined, we will discuss the potential consequences of DM
mis-splicing on Tau function.
Tau protein structure
Tau is a “natively unfolded” protein (Schweers et al., 1994;
Jeganathan et al., 2008), but short sequences (maximum of 10
residues) transiently adopt secondary structures, facilitating tran-
sient functions such as protein-protein interactions (Mukrasch
et al., 2009). In solution, Tau adopts a “paperclip” structure result-
ing from interactions between the N and C termini of the Tau and
microtubule-binding domains (MBDs). This structure is inde-
pendent of the presence/absence of exons 2, 3, and 10 (Jeganathan
et al., 2008).
The Tau protein has been divided into various regions based
on chemical (basic, acidic, neutral), biochemical (proline-rich
domain (PRD), hinge region, repeats), or functional features
(projection domain, microtubule-binding region). As shown in
Figure 3, the insertion of alternatively spliced exons extends the
different domains in which these sequences are inserted: exons 2,
3, and 4A lengthen the acidic region and, consequently, the pro-
jection domain, whereas exons 6c and 10 length the basic region,
PRD, and MBR. None of the additional alternative sequences
disrupt the properties of the domain in which they are inserted.
Effects of mis-splicing on Tau binding to membranes and its
secretion
The N terminus of Tau (amino acids 2–18) has been implicated
in its binding to the plasma membrane. Although the exon 2-
encoded sequence is located proximal to this site, there are no
reports on the influence of this sequence and its phosphorylation
on Tau binding to membranes. However, an effect of the exon 2-
encoded sequence on the secretion of N-terminal fragments has
been reported (Kim et al., 2010).
Effects of mis-splicing on tau aggregation
The microtubule-binding repeats (MBRs) are essential for Tau
fibrillization, whereas the flanking regions are inhibitory (Wille
et al., 1992; Alonso et al., 2001). Two short peptides encoded by
exons 11 (PHF6) and 10 (PHF6∗) have been identified as major
factors in the aggregation of Tau (Von Bergen et al., 2000, 2001; Li
and Lee, 2006). The first motif, encoded by exon 11, is sufficient
to promote aggregation, whereas the second motif, encoded by
exon 10, facilitates aggregation. Thus, a loss of Tau isoforms with
4 MBRs would prevent the aggregation of this protein.
The role of the exon 2-encoded sequence in Tau aggrega-
tion has recently been described. The exon 2-encoded sequence
promotes the fibrillar extension of Tau filaments but does not
promote the nucleation of Tau aggregates (Zhong et al., 2012).
By contrast, the inclusion of the Tau exon 3-encoded sequence
diminishes the fibrillar extension, consistent with a potential pro-
tective effect of exon 3, as suggested by its higher inclusion in
association with the H2 haplotype, a protective haplotype with
respect to tauopathy development, compared with H1 haplo-
type (Trabzuni et al., 2012). However, Tau hyperphosphorylation
might interfere with the aggregation of Tau isoforms. Indeed,
in a cellular model, Tau pseudo-phosphorylation at sites com-
mon to the different Tau isoforms inhibits the aggregation of
all 3R isoforms but has little effect on the aggregation of 2N4R
(2+3+10+ isoform) and 1N4R (2+10+ isoform), and enhances
the aggregation of 0N4R (10+ isoform) (Combs et al., 2011).
Altogether, these observations suggest that the decrease in the
inclusion of exons 2, 3, and 10 in DM1 might be protective with
respect to Tau aggregation in DM1. However, note that the toxi-
city of aggregated tau is yet a matter of debate. A possible role of
these aggregates in neuroprotection as well as a toxicity of soluble
forms of Tau have been reported and recently reviewed in Cowan
and Mudher (2013).
Effects of mis-splicing on protein-protein interactions
Tau carries many ionic charges and contains a PRD, which enable
it to potentially interact with many protein partners; however,
these interactions are transient and difficult to detect.
Interaction studies have primarily been performed using the
longest isoform of Tau (2N4R) first identified in the brain or
some region of this isoform [for a review, see Mandelkow and
Mandelkow (2012)]. Only interactions with sequences encoded
by exons 2, 3, and 10 might be reduced or promoted in DM1
compared to control. As described below, while Tau protein inter-
actions with microtubules are dependent on the insertion or
omission of the sequence encoded by exon 10, these interactions
might also depend on the phosphorylation state of the protein,
particularly in the MBR and neighboring regions [reviewed in
Sergeant et al. (2005)]. HSP70 binding to Tau affects microtubule
polymerization and efficiently inhibits Tau aggregation (Dou
et al., 2003; Sahara et al., 2007; Voss et al., 2012). These effects are
isoform dependent. The anti-aggregative effect of HSP70 is higher
for 3R isoforms than 4R isoforms. Thus, these results are also in
agreement with the moderate development of the tauopathy in
the DM1 brain.
Exon 6c is the most frequent form of exon 6 inclusion, but no
data concerning its possible interactions with other partners are
available. Exon 6c inclusion lengthens the PRD, and the encoded
sequence is rich in putative sites of phosphorylation, features
that modulate protein functions and interactions. In addition
to the 85 putative sites present on the 2N4R isoform, the exon
6c-encoded insert (66 amino acids) introduces 22 new putative
sites of phosphorylation (21 Ser/Thr and 1 Tyr, i.e., 1/3 residues),
four of which could be proline-dependent. However, the impact
of the exon 6c-encoded sequence on Tau phosphorylation is yet
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unknown. Although Tau containing exon 6c-encoded sequence
binds microtubules, it might serve as an inhibitor of axon elonga-
tion, particularly when the Tau isoforms also contain exon 2- and
exon 3-encoded sequences (Luo et al., 2004a,b).
Effects of mis-splicing on microtubule stabilization and axonal
transport
The MBR comprises three (3R) or four (4R) tubulin-binding
repeats depending on the insertion or omission of the sequence
encoded by exon 10. The insertion of a fourth microtubule-
binding domain (the second one in the primary structure of
the protein) enhances microtubule binding by Tau by 40-fold
and, consequently, also enhances the stability of the microtubules
(Goode and Feinstein, 1994). Consequently, 4R-Tau is a potent
inhibitor of MT shortening, in contrast to the 3R-Tau isoforms
(Bunker et al., 2004). In the human adult brain, the ratio between
3R and 4R is 1:1, and both the 3R and 4R proteins are detected
throughout the brain (Mulot et al., 1994; Boutajangout et al.,
2004; Trabzuni et al., 2012). Thus, the loss of the Tau 4R pro-
tein observed in DM1 might result in a loss of microtubule
stabilization and an increase in neuronal plasticity.
The Tau 3R/4R balance could also affect other Tau prop-
erties. Indeed, Tau affects organelle transport by reducing the
attachment frequency of motors to microtubules (Sato-Harada
et al., 1996; Trinczek et al., 1999; Seitz et al., 2002; Mandelkow
et al., 2004) or differentially regulating kinesin- and dynein-based
transport (Dixit et al., 2008; Vershinin et al., 2008). According to
Dixit et al. (2008), Tau interferes with anterograde transport by
inducing kinesin detachment. However, by reversing the direc-
tion of dynactin-dynein motor proteins, Tau also interferes, to
a lesser extent, with retrograde transport. The perturbations of
kinesin and dynein-dynactin migration are both dependent on
the Tau isoform; the shortest Tau isoform (0N3R) is a more
potent inhibitor than the longest isoform (2N4R) (Dixit et al.,
2008). Thus, the overexpression of the fetal form (0N3R) and
the disappearance of the adult forms might lead to an increased
perturbation of axonal transport in the DM1 brain compared
to other tauopathies, such as AD, as well as increased neuronal
plasticity. Interestingly, both the N- and C-halves of Tau inter-
fere with kinesin-mediated axonal transport. First, Tau 3R has a
more significant effect than Tau 4R on both kinesin and dynein
binding and progression along stabilized microtubules (Vershinin
et al., 2007, 2008; Stoothoff et al., 2009), while Tau 4R but
not Tau 3R enhances the velocity of kinesin (McVicker et al.,
2011). Second, the N terminus inhibits fast anterograde transport
(FAT) by activating the PP1–GSK3 pathway due to the exposure
of the phosphatase-activating domain (PAD) in aggregated Tau
(LaPointe et al., 2009; Kanaan et al., 2011). However, the phos-
phorylation of Tau Y18, an AD-specific phosphorylation site and
Fyn substrate, prevents the effect of Tau on FAT (Kanaan et al.,
2012). Note that sequences encoded by exons 2 and 3 lengthen
the Tau projection domain, resulting in an increase in the space
between microtubules (Kanai et al., 1992). Thus, these sequences
might reinforce the effects of Tyr18 phosphorylation on axonal
transport. Indeed, the space between microtubules was recently
shown to be a potential determinant in mitochondrial transport
(Shahpasand et al., 2012).
Axonal transport also depends on Tau exon 6 splicing. The 6p-
and 6d-containing forms are sufficient to perturb FAT because
these short isoforms cannot adopt the “paperclip conformation”
in the absence of the C-terminus, leading to the spontaneous
exposure of the PAD domain (LaPointe et al., 2009; Kanaan
et al., 2011). Thus, although exon 6 is a minor cassette in DM1,
the increase in 6d levels could contribute, even weakly, to the
disruption of axonal transport in DM1 patients.
In conclusion, by favoring the fetal Tau isoform (0N3R) and
increasing the minor 6d forms, changes in Tau alternative splicing
might result in a variation of microtubule bundle organization
and axonal transport in the DM1 brain and an enhanced secretion
and diminished aggregation of Tau.
COMMON FEATURES OF DM AND OTHER TAUOPATHIES
The term tauopathy merges nearly 30 diseases characterized by
Tau aggregation and neurodegeneration due to various factors,
such as genetic (mutations or polymorphisms/haplotypes of dif-
ferent genes), environmental (trauma), and molecular factors
(with or without amyloid cascade contributions) [reviewed in
Sergeant et al. (2005)]. In DM, the expansion of oligonucleotide
repeats (CTG/CCTG) leads to tauopathy. Thus, there are inter-
connections of the different pathways that are initiated by distinct
factors and lead to both tau aggregation and neurodegeneration.
What are the common determinants and crucial steps of these
different diseases that contribute to tauopathy development?
TAU MIS-SPLICING
Tau mis–splicing has been implicated in tauopathy development
since the discovery that Tau mutations in intronic sequences
resulted in both splicing deregulation and tauopathy in FTDP-
17 cases. Indeed, Tau mis-splicing has been identified in various
tauopathies, such as FTDP-17, PSP, CBD, argyrophilic grain dis-
ease, DM, and, to a lesser extent, AD and Down syndrome
(Sergeant et al., 2005). Notably, the mechanisms of mis-splicing
might differ according to the disease. In FTDP-17, mis-splicing is
due to cis-factors, i.e., Tau mutations, at sites involved in splic-
ing factor binding. In DM, mis-splicing is due to a disruption
in the ratio of some splicing regulator trans-factors, particularly
those belonging to the CELF and MBNL families. In other cases,
such as PSP and CBD, the mechanisms differ according to famil-
ial or sporadic forms of the disease. In familial cases, Tau 4R
over-expression results from Tau mutations in the binding site
of regulator factors. In sporadic forms, Tau 4R over-expression
is dependent on the Tau haplotype. Indeed, the H1MAPT haplo-
type has been consistently associated with PSP (Rademakers et al.,
2005). Down-regulation of miR-132 in the brains of PSP patients
was recently reported. Furthermore, silencing of this miR leads
to an increase in the ratio of the Tau 4R/3R isoforms (Smith
et al., 2011). Thus, in some tauopathies, mis-splicing could be
associated with variations in miR expression.
Taken together, these data indicate that dysregulation of the
balance between the different Tau isoforms is a sufficient fac-
tor to trigger tauopathy. Although an increase in Tau 4R levels
is the most frequent dysregulation observed in FTDP-17, PSP,
and CBD, the overexpression of 3R isoforms is associated with
tauopathies such as rare FTDP-17 cases and PiD. In these different
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pathologies, no splicing error in exons 2 or 3 has been reported.
The DMs are the first pathologies in which global indirect Tau
mis-splicing, i.e., errors in the splicing of exons 2, 3, 6, and 10,
have been observed (Sergeant et al., 2001, 2008; Jiang et al., 2004;
Leroy et al., 2006b).
Conflicting data concerning AD have been reported. Mis-
splicing is difficult to demonstrate in whole tissues because only
some neurons, particularly cholinergic neurons, are degenerat-
ing. The number of degenerating neurons is a function of the area
and stage of the pathology. Thus, some studies have not detected
changes in splicing during AD, while others have reported an
increase in exon 10 inclusion, although this increase is lower
than that observed for other tauopathies (Baker et al., 2000;
Boutajangout et al., 2004; Connell et al., 2005; Glatz et al., 2006;
Ingelsson et al., 2006; Conrad et al., 2007; Abraham et al., 2009).
Only one study reported an alteration in exon 2 splicing, which
involved a decrease in exon 2 inclusion. Interestingly, an increase
in exon 3 inclusion has been reported in cells and subjects with
the H2 haplotype (Conrad et al., 2007; Caffrey et al., 2008; Wegiel
et al., 2011; Trabzuni et al., 2012), which is protective compared
with H1. A study of Down syndrome patients developing ADwith
aging suggests an increase in exon 10 exclusion (Wegiel et al.,
2011).
DIABETES AND METABOLIC SYNDROME
Another common feature of DM1 and some tauopathies
involves insulin metabolism and associated diseases. Although
the importance of insulin resistance in DM remains controver-
sial (Perseghin et al., 2004), DM1 patients exhibit peripheral
insulin resistance with glucose intolerance, hyperinsulinemia, and
an increased risk of developing type II diabetes (T2DM) (5–17%
of patients) (Moxley et al., 1984; Savkur et al., 2001; Rakocevic
Stojanovic et al., 2010; Kaminsky et al., 2011). This peripheral
insulin resistance might be due to the IR splicing alterations
observed during DM (Savkur et al., 2001, 2004). However, the
relationship between IR splicing, insulin resistance, and T2DM is
unclear. Although the overexpression of IR A (i.e., the IR isoform
without the exon 11-encoded sequence) has been reported in one
T2DM case with extreme insulin resistance and hyperinsulinemia
(Norgren et al., 1994), a decrease in the IR A form has been more
frequently reported in T2DM (Mosthaf et al., 1991; Sesti et al.,
1991; Kellerer et al., 1993; Norgren et al., 1993). However, this
alteration has not been observed by other groups (Benecke et al.,
1992; Anderson et al., 1993; Hansen et al., 1993). By contrast, an
increase in IR A expression similar to that observed in DM1 has
been evidenced in obese and early-stage diabetic rhesus monkeys,
supporting the hypothesis of a relationship between IR splicing
and diabetes (Huang et al., 1994, 1996).
Interestingly, metabolic syndromes, including T2DM, are also
a significant risk factor for AD [reviewed in Frisardi et al. (2010),
Bosco et al. (2011)]. Hyperglycemia leads to an excessive periph-
eral utilization of insulin, resulting in reduced insulin transport
to the brain. Brain insulin plays a role in neuron survival, learn-
ingmemory, synaptic plasticity, and neuronal energy homeostasis
[reviewed in Belfiore et al. (2009)]. Intranasal administration of
insulin has potential beneficial cognitive effects, confirming the
possible deleterious impact of insulin in AD (Reger et al., 2008;
Shemesh et al., 2012). Insulin could interfere with pathological
processes at various stages. First, insulin resistance has been sug-
gested to be involved in cognitive impairment (Bruehl et al.,
2010). Second, insulin might accelerate AD-related pathology
through its effects on amyloid beta (Aβ) metabolism and Tau
phosphorylation [reviewed in Bosco et al. (2011)]. Interestingly,
intranasal insulin partially corrects Tau hyperphosphorylation in
diabetic rats (Yang et al., 2013). Third, the increased expression of
three-repeat isoforms of Tau could contribute to the Tau pathol-
ogy in a rat model of chronic type 2 diabetes (Jung et al., 2011).
Notably, increases in both Tau phosphorylation and Tau 3R lev-
els have also been observed in DM1 patients. Furthermore, in the
absence of peripheral insulin resistance but up-regulation of hip-
pocampal insulin signaling, early and progressive obesity poten-
tiated spatial learning deficits and hippocampal Tau pathology
at a later stage in transgenic THY-Tau22 mice (Leboucher et al.,
2013). Interestingly, Tau phosphorylation and/or Aβ oligomer-
ization/aggregation have been observed in several diabetic mouse
or rabbit models, confirming a possible relationship between AD
disease and diabetes (Li et al., 2007; Planel et al., 2007; Jolivalt
et al., 2010; Bitel et al., 2012; Papon et al., 2013).
COMMONMOLECULAR ACTORS IN DM AND AD
Various molecular actors are common between DM and
tauopathies such as AD and are therefore of particular inter-
est for understanding pathological processes. The contribution
of these different actors to Tau aggregation and neurodegenera-
tion has not been well-elucidated. Nevertheless, the deregulation
of the function of these proteins could be a metabolic event
contributing to the common pathological aspects of these dis-
eases, i.e., the development of a tauopathy. Thus, we will discuss
these common actors and how they are involved in either DM or
tauopathy.
Bin-1
Tau is not the only transcript targeted by the DM1 mutation
that is ubiquitously expressed, but the DM1 mis-splicing is often
reported for only one tissue. For Bin-1, the preferential exclu-
sion of muscle-specific exon 11 has been reported in DM1muscle
compared with healthy persons and has been associated with
T tubule alterations and muscle weakness (Fugier et al., 2011).
Other exons of Bin-1 such as exons 7 and 13–16, are brain spe-
cific, but their eventual mis-splicing has not been investigated,
and therefore the contributions of these entities cannot be ruled-
out. Although Bin1 mis-splicing has not been established in the
DM brain, Bin1 is a recently identified genetic marker for pre-
disposition to the most frequent tauopathy, AD (Seshadri et al.,
2010; Carrasquillo et al., 2011; Lambert et al., 2011; Logue et al.,
2011; Wijsman et al., 2011). A particular variant, located 28 kb
upstream of Bin-1, has been associated with risk for AD, particu-
larly the Tau load in the brains of AD patients. This SNP results
in the increased expression of Bin-1. Bin-1 is highly expressed in
neuronal tissue, and its role in neurons must be accurately deter-
mined. Bin-1 is suspected to interfere with synaptic function and
cell membrane processes and might be associated with receptor-
dependent signaling pathways (Leprince et al., 1997; Morgan,
2011). Interestingly, Bin-1 interacts with Tau proteins (Chapuis
et al., 2013).
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APP
Jiang et al. (2004) reported a default in APP splicing in DM1
patients, characterized by a decrease in exon 7 inclusion. The
sequences encoding exons 7 and 8 are specifically excluded from
the neuronal APP form (APP695) but are included in astrocytic
APP isoforms (APP 751, APP770). Interestingly, a change in the
APP splicing pattern has also been observed in the brains of AD
patients. In contrast to the DM brain, the modified splicing cor-
responds to an increase in exon 7 inclusion in the AD brain
(Johnson et al., 1989; Tanaka et al., 1989). However, changes in
APP splicing are somewhat difficult to interpret because APP is
expressed in both neurons and astrocytes. An increase in exons 7
and 8 might either correspond to the mis-splicing of APP tran-
scripts in neurons or result from neuronal loss or astrocytosis,
both events observed in AD (Donev et al., 2009; Rodriguez et al.,
2009). In DM1, a decrease in exon 7 inclusion might be indica-
tive of mis-splicing in astrocytes. The functional consequences of
changes in APP splicing in astrocytes remain ill-defined.
In addition to mis-splicing, defects in APP metabolism
have been strongly associated with the development of some
tauopathies, particularly AD [recently reviewed in Huang and
Mucke (2012)]. Indeed, APP proteolysis is modified during AD,
favoring the production of Aβ1-42 or Aβ N-42 peptides, which
aggregate in the extracellular space. Aβ1-42 dosage is one of the
three biological markers indicative of an AD diagnosis: Aβ1-42 is
decreased in the cerebrospinal fluid (CSF) of AD patients, whereas
total Tau and phosphorylated Tau levels are increased (Blennow
and Hampel, 2003; Herukka et al., 2005; Bombois et al., 2013).
Decreased Aβ1-42 levels in the CSF have also been observed in
various tauopathies and other diseases, such as Creutzfeld-Jacob
disease andMultiple System Atrophy (Van Everbroeck et al., 1999;
Otto et al., 2000; Sjogren et al., 2002; Noguchi et al., 2005).
Interestingly, the analysis of CSF in DM patients also revealed a
significant decrease in Aβ1-42 compared with matched controls
(Winblad et al., 2008; Peric et al., 2013a). While a decrease in the
Aβ1-42 level in the CSF of AD patients is associated with the pres-
ence of the cerebral aggregation of this peptide, this is not the
case for other tauopathies, particularly DM (Kiuchi et al., 1991;
Figure 1).
NMDAR
In the DM1 brain, defective splicing of NMDA-R1 is observed,
which, in conjunction with altered Tau splicing, suggests defec-
tive neuronal plasticity. This splicing change corresponds to an
increase in exon 5 inclusion in NMDAR1 transcripts (Jiang et al.,
2004) and could result in the functional modification of the
protein, although this possibility remains to be determined. N-
methyl-D-aspartate receptors (NMDAR) are multimeric ligand-
gated ion channels comprising at least one member of the NMDA
receptor 1 subunit (NMDAR1) family and one of four different
subunits of the NR2 family (NMDAR2 A-D). These receptors play
a role in neuronal plasticity, but over-activation of these receptors
results in excitotoxic damage (Chandler et al., 1998; Jaekel et al.,
2006). The NMDAR1 family comprises eight alternatively spliced
variants generated through the alternative splicing of exons 5, 21,
and 22 (Laurie and Seeburg, 1994; Zukin and Bennett, 1995). The
splicing pattern varies during development, across brain regions,
and among subtypes of neurons. The presence of exon 5-encoded
sequences determines the sensitivity of NMDAR to protons and
polyamines and accelerates receptor deactivation after brief ago-
nist exposure (Traynelis et al., 1995, 1998; Rumbaugh et al.,
2000).
Interestingly, a pivotal role for NMDAR-mediated toxicity has
been suggested in AD and tauopathies. Indeed, an overactivation
of N-methyl-D-aspartate glutamate (NMDA) receptors, which
permits excessive Ca2+ influx through associated ion channels,
would induce damage and neuronal cell death. NMDAR func-
tion can also be modulated through the metabolite products of
APP and Tau, proteins essential to AD development. Indeed, the
over-expression of human Tau and its N-terminal fragments in
primary neuronal cultures leads to N-methyl-D-aspartate recep-
tor (NMDAR)-mediated cell death. As a feedback loop, NMDAR
stimulation causes calpain activation, followed by Tau protein
proteolysis, resulting in highly toxic N-terminal peptides, such
as the 17-kDa peptide (Amadoro et al., 2006). This feedback
might be associated, at least in part, with the presence of Tau
in the dendritic spines and the axonal localization of this pro-
tein. Moreover, naturally secreted Aβ dimers and trimers but not
monomers induce the progressive loss of hippocampal synapses,
mediated through the activity of NMDARs (Shankar et al., 2007).
Thus, NMDAR antagonists, such as Memantine, a drug that
blocks ion channel formation mediated through NMDARs, are
presently used in AD treatment [reviewed in Schmitt (2005) and
Dominguez et al. (2011)]. Memantine might also inhibit Tau and
APP protein translation, mediated through the internal ribosome
entry site (IRES) of their transcripts. Thus, Memantine inhibits
the neuronal expression of Tau and APP proteins, two essential
actors in AD (Wu and Chen, 2009). Memantine has also been
reported to block the increase in Ca2+ flux and oxidative stress
induced through soluble Aβ oligomers (De Felice et al., 2007).
CELF2
CELF proteins, particularly CELF1 and CELF2, play an important
role in DM1mis-splicing. In the brain, CELF2 regulates the splic-
ing of NMDAR exon 5 and Tau exons 2 and 3, thus acting as a
silencer, whereas CELF1 is inefficient (Zhang et al., 2002; Leroy
et al., 2006a; Dhaenens et al., 2011). Curiously, the genome-wide
association of familial late-onset AD with CUGBP2 SNPs has
been reported in patients with ApoE e4/e4 genotypes, i.e., patients
with high risk of developing late-onset AD (Wijsman et al., 2011).
However, the relationship between CELF2 SNPs and AD has not
been elucidated.
BEYOND TAUOPATHY
A TOXIC GAIN-OF-FUNCTION OF RNA
As detailed in the two preceding sections, Tau mis-splicing
induced by CTG mutation has been suggested to be sufficient to
induce tauopathy. But is tauopathy sufficient to explain all the
brain defects in DM1? Animal models could be useful to answer
this question. Two animal models have been described to develop
brain pathology: the MBNL2-KO mouse model and transgenic
CUG SXXL mice (Gomes-Pereira et al., 2007; Charizanis et al.,
2012; Huguet et al., 2012). To date, no data concerning an
eventual tauopathy in these models have been reported.
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Interestingly, Tau pathology has also been observed in some
mixed amyotrophic lateral sclerosis (ALS)/FTD cases bearing
GGGGCC expansions in C9ORF72, suggesting that some patients
with nucleotide repeat expansions could develop a mixed pathol-
ogy (Bieniek et al., 2013; King et al., 2013). Moreover, this
observation also suggests a close relationship between oligonu-
cleotide expansion, neuropathology, and tauopathy, and in the
absence of mis-splicing, tauopathy could be a secondary con-
sequence of neuropathy associated with oligonucleotide repeat
expansion. Thus, it would be interesting to identify tauopathy in
other diseases with repeat expansions.
However, other observations argue that some neurologi-
cal dysfunctions occur independent of tauopathy development.
Indeed, it is strange that all expanded repeat mutations, which
cause more than 20 diseases, lead to neuropathologies. Why is
this type of mutation preferentially associated with this type of
disease? The repeat expansions differ with respect to their iden-
tity, number, and functional consequences and are harbored by
different genes, leading to differential patterns of tissue expres-
sion. These pathologies present divergent pathological pathways;
in particular, these expansions can either affect protein function
or result in a gain of toxic function of the mutated RNA. A gain
of toxic function of the mutated RNA was first reported in a study
concerning DM1 and subsequently reported for other patholo-
gies, such as HDL2, SCA8, 10, 31, FXTAS, and more recently,
FTD, amyotrophic lateral sclerosis (ALS), mixed ALS/FTD cases,
and SCA36 [reviewed in La Spada and Taylor (2010), DeJesus-
Hernandez et al. (2011), Renton et al. (2011), Wojciechowska and
Krzyzosiak (2011), Garcia-Murias et al. (2012), Ikeda et al. (2012),
Simon-Sanchez et al. (2012)]. These pathologies are character-
ized by a nuclear aggregation of mutated transcripts (called foci)
and a change in the alternative splicing of numerous transcripts.
The protein trapped by the foci is dependent on the pathologies.
Indeed, nuclear foci can sequester MBNL1 proteins in patholo-
gies with CUG, CCUG, or CAG, CGG repeat expansions (Miller
et al., 2000; Fardaei et al., 2002; Rudnicki et al., 2007; de Mezer
et al., 2011) and hnRNPK in SCA10 (White et al., 2010) and
Sam68 in FXTAS (CGG expansion), which also recruit MBNL1
and hnRNPG in foci (Iwahashi et al., 2006; Sellier et al., 2010).
Recent reports have suggested that the distinction between dis-
eases with expanded oligonucleotide repeats characterized by a
gain of RNA function and those characterized by a gain of pro-
tein function is not so obvious [reviewed in Batra et al. (2010)].
SCA8 is the first disease for which bidirectional transcription
leading to both RNA and protein dysregulation has been reported
(Moseley et al., 2006). Indeed, a newly defined molecular mech-
anism, “repeat-associated non-ATG initiated translation (RAN
translation),” results in the accumulation of SCA8 polyalanine
and DM1 polyglutamine in, respectively, SCA8 and DM1 human
tissues and mouse models (Zu et al., 2011). Nevertheless, the
contribution of these proteins to disease pathology has not been
elucidated. Similarly, both nuclear foci and polyglutamine pro-
tein aggregation have been reported in HDL2, another CTG
expansion disease (Holmes et al., 2001; Rudnicki et al., 2007;
Wilburn et al., 2011). Other mechanisms, such as haploinsuf-
ficiency, anti-sense RNA, and miRNA, have been suggested to
interfere with pathology development [recently reviewed in Klein
et al. (2011), Sicot et al. (2011); Udd and Krahe (2012)]. Thus, the
neurological specificity of these pathologies might be determined
by the as-yet undetermined pathological processes that they
share.
SPLICEOPATHY AND NEUROLOGICAL DISORDERS
Alternative splicing is involved in numerous neurological diseases
and can be associated with either the disruption of cis-splicing
sites or trans-acting factors [reviewed in Mills and Janitz (2012);
Feng and Xie (2013)]. In addition to diseases with a gain of toxic
RNA function (described above) and tauopathy associated with
Tau mis-splicing (see Part III), a relationship between splicing
and neuronal dysfunction has been demonstrated for other neu-
rological pathologies, such as spinal muscular atrophy (SMA).
SMA is a recessive autosomal disease associated with the dys-
function of the survival of motor neurons protein (SMN), a
RNA-binding protein required for the efficient assembly of small
nuclear ribonucleoprotein (snRNP) complexes and spliceosomal
snRNP biogenesis. This protein has therefore been indirectly
implicated in general cellular RNA processing. By modifying the
pre-mRNA splicing machinery, mutated SMN might interfere
with mRNA biogenesis (Lefebvre et al., 1995; Pellizzoni et al.,
2002; Zhang et al., 2008). Moreover, Lotti et al. (Lotti et al., 2012)
recently demonstrated that SMN interferes with the U12 splic-
ing mechanism, a minor alternative process to classical splicing,
and SMN depletion alters the splicing of 18 exons, particularly in
Stamsimon transcripts, resulting in motor neuron degeneration.
SMN also binds FMRP, a defective protein in Fragile X mental
retardation syndrome that is associated with mRNA transport
and translation (Piazzon et al., 2008).
Other neurological pathologies associated with the dysfunc-
tion of RNA-binding factors include ALS and FTD, which is
induced by mutations in the TDP-43 and FUS genes (Kabashi
et al., 2008; Sreedharan et al., 2008; Vance et al., 2009). TDP43
regulates the splicing of several human transcripts, particularly
those of SMN, serine/arginine-rich splicing factor 2 (SC35), S6
kinase 1(S6K1), and Aly/REF-like target (SKAR), a component
of the exon junction complex (EJC) (Bose et al., 2008; Dreumont
et al., 2010; Tollervey et al., 2011; Fiesel et al., 2012). Consistent
with its function as an RNA-binding protein, TDP-43 associates
with many other RNA-binding proteins, such as hnRNP A2/B1,
hnRNP A1, hnRNP C1/C2, hnRNP A3, and FUS (which is
involved in splicing processes and whose mutations are respon-
sible for 5% of FTD) (Yang et al., 1998; Buratti et al., 2005;
Freibaum et al., 2010; Ling et al., 2010). Furthermore, the loss
of TDP-43 has recently been associated with long pre-mRNA
depletion, RNA mis-splicing (Polymenidou et al., 2011; Tollervey
et al., 2011), and a potential role for TDP-43 in axonal mRNA
regulation and miRNA biogenesis associated with neuronal
outgrowth (Fallini et al., 2012; Kawahara and Mieda-Sato, 2012).
The role of FUS, the second protein involved in ALS/FTD, as a
brain RNA splicing regulator (Rogelj et al., 2012), particularly
for Tau and RNA-binding protein splicing (Orozco et al., 2012;
Nakaya et al., 2013), has only recently been described. Both
FUS and TDP-43 preferentially bind to extra-long introns, likely
to protect these regions from incorrect splicing at cryptic sites
(Lagier-Tourenne et al., 2012).
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FIGURE 4 | The complex interaction between RNAopathy,
spliceopathy, and tauopathy. DM diseases are the first pathologies for
which these interactions have been established.
Although mis-splicing has clearly been demonstrated for vari-
ous pathologies, including some tauopathies, recent studies have
indicated the dysfunction of different splicing regulators in other
diseases; however, a clear relationship with a particular splic-
ing event has not been established in these latter diseases [see
review Mills and Janitz (2012)]. The hnRNP A1 polymorphism
is a genetic factor for some FTLD (Villa et al., 2011), and mutated
RBFox1 has been associated with mental retardation, epilepsy,
and autism spectrum disorders (Bhalla et al., 2004; Barnby et al.,
2005; Martin et al., 2007; Sebat et al., 2007). SRP20, TDP-43,
hnRNP-A/B, and CELF2 have been associated with AD (Amador-
Ortiz et al., 2007; Uryu et al., 2008; Wijsman et al., 2011; Berson
et al., 2012; Wong et al., 2012), and SFPQ has been associated
with AD and PiD (Ke et al., 2012). These observations suggest
that the involvement of RNA-binding proteins, particularly splic-
ing regulator factors, largely contributes to the neurodegenerative
process. Indeed, these factors can be involved in numerous splic-
ing events, and the modulation of their activity resulting from the
modification of the expression and localization of these factors
could explain the variations in the alternative splicing of var-
ious transcripts detected in neurodegenerative diseases such as
AD, Parkinson’s disease, and schizophrenia (Twine et al., 2011;
Cohen et al., 2012; Soreq et al., 2012;Wu et al., 2012; Wong, 2013)
[recently reviewed in Cooper-Knock et al. (2012)]. However,
these factors assume other functions, such as RNA export and
RNA stabilization. Thus, a role of these factors in pathology
through mechanisms other than splicing alterations cannot be
excluded.
The deregulation of splicing could also result from snRNP
deregulation, as recently suggested for AD. The accumulation of
both U1SnRNP and U1-70K, elements essential to the splicing
mechanism, has recently been associated with AD and unspliced
RNA accumulation (Bai et al., 2013).
Taken together, these examples indicate that the modifica-
tion of the splicing factor pool and the deregulation of snRNPs
involved in splicing exert a toxic effect in humans; thus, the
modification of the splicing pool induced by DM1 mutations
might also be associated with neuronal dysfunctions other than
tauopathies and Tau splicing alterations.
CONCLUSION
DM is the first pathology identified as a combination of tauopa-
thy, spliceopathy, and RNAopathy. Indeed, DM1 is the first iden-
tified pathology for which the tauopathy has been associated with
an expansion of oligonucleotide repeats (Sergeant et al., 2001). It
has been hypothesized that this DM-associated tauopathy might
result from Tau mis-splicing induced through RNAopathy. This
relationship between Tau mis-splicing and tauopathy has previ-
ously been reported for some FTD, and particularly for some
cases of FTDP-17 with specific Tau mutations. However, Tau
mis-splicing is only one among other molecular mechanisms for
the induction of tauopathy. Indeed, other tauopathies have been
associated with mutations in different genes: APP, PS1, and PS2
(three genes involved in the amyloid cascade in AD);MAPT (Tau
gene) (other mutations than those involved in splicing default),
or the MAPT haplotype. Thus, various pathological mechanisms
lead to tauopathy development, such as Tau mis-splicing in some
cases of FTDP-17 and the amyloid cascade in AD, explaining
why these pathologies, although clinically different, share several
molecular features, as described in this review and schematized in
Figure 4.
A complex interaction between RNAopathy, spliceopathy, and
proteinopathy other than tauopathy has also been observed in
other neurological diseases (Figure 4). Although these patholo-
gies differ according to the nature and length of the microsatellite
repeats, the aggregated proteins, clinical symptoms, and histolog-
ical features, this interaction between RNAopathy, spliceopathy,
and proteinopathy might be an essential inducer of the patholog-
ical mechanisms specific for neurological deregulation. Given the
association between tauopathy, spliceopathy and RNAopathy in
DM, it would be interesting to determine whether tauopathies are
also associated with other diseases involving microsatellite expan-
sions and investigate whether this association is not specific to
DM but is rather a more global mechanism in which spliceopathy,
RNAopathy, and proteinopathy converge.
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